Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) (AA 145-159), (Internal Region) antibody

Details for Product No. ABIN498022
Antigen
  • zgc:85888
  • AGM
  • FSTL2
  • IBP-7
  • IGFBP-7
  • IGFBP-7v
  • IGFBPRP1
  • MAC25
  • PSF
  • RAMSVPS
  • TAF
  • Fstl2
  • Mac25
  • insulin like growth factor binding protein 7
  • insulin-like growth factor binding protein 7
  • IGFBP7
  • igfbp7
  • Igfbp7
Epitope
Internal Region, AA 145-159
15
9
8
6
6
6
4
2
1
1
1
1
Reactivity
Human, Mouse (Murine), Rat (Rattus)
103
57
42
4
2
2
2
2
2
2
1
1
1
Host
Goat
97
18
8
1
Clonality
Polyclonal
Conjugate
Un-conjugated
11
4
4
3
3
3
3
3
3
2
2
2
1
1
1
1
1
Application
Enzyme Immunoassay (EIA), Western Blotting (WB)
83
68
34
15
13
11
8
7
5
2
2
1
1
Options
Immunogen Peptide with sequence from the internal region of the protein sequence according to NP_006423.1. Genename: IGFBP7
Sequence EKAITQVSKG TCEQG
Specificity Recognizes IGFBP7 (145-159).
Cross-Reactivity (Details) Species reactivity (expected):Human, Rat.
Species reactivity (tested):Mouse.
Purification Ammonium Sulphate Precipitation followed by Antigen Affinity Chromatography using the immunizing peptide.
Antigen
Alternative Name IGFBP7 (IGFBP7 Antibody Abstract)
Background IGF-BPs form high affinity complexes with both IGF-I and IGF-II and act to control of the distribution, function and activity of IGFs in various cell tissues and body fluids. There are seven named IGF-BPs. IGFBP7 plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGFBP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. IGFBP7 is expressed in a wide range of normal human tissues and it usually shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.Synonyms: IBP-7, IBP7, IGF-binding protein 7, IGFBP-7, IGFBP-rP1, Insulin-like growth factor-binding protein 7, MAC25, PGI2-stimulating factor, PSF, Prostacyclin-stimulating factor, TAF, Tumor-derived adhesion factor
Gene ID 3490
NCBI Accession NP_001544
UniProt Q16270
Pathways Growth Factor Binding
Application Notes Peptide ELISA: Limit Dilution: 1/8000. Western blot: 1-3 μg/mL. Approx 30 kDa band observed in Mouse Kidney lysates (calculatedMW of 29.0 kDa according to Human NP_001544.1 and to Mouse NP_032074.3).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Concentration 0.5 mg/mL
Buffer Tris saline, pH 7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Supplier Images
Image no. 1 for anti-Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) (AA 145-159), (Internal Region) antibody (ABIN498022) AP20109PU-N staining of Mouse Kidney lysate at 1 µg/ml (RIPA buffer, 35 µg total prot...
Background publications Evans, Johnson, Laurenson, Davies, Ko Ferrigno, Wälti: "Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays." in: Journal of biology, Vol. 7, Issue 1, pp. 3, 2008 (PubMed).

Did you look for something else?